Gritstone Oncology, Inc. is a clinical-stage biotechnology company developing cancer immunotherapies to fight multiple cancer types. The company's approach is to use the patient's immune system to identify and destroy cancer cells. Gritstone Oncology's product candidates include personalized cancer immunotherapies, off-the-shelf cancer immunotherapies, and bispecific antibodies. The company's lead product candidate, GRANITE, is a personalized cancer immunotherapy that targets tumor-specific neoantigens. Gritstone Oncology, Inc. was founded in 2015 and is headquartered in Emeryville, California.